FTI Consulting Survey: US Healthcare & Life Sciences Industry Outlook 2023

Facing Forward: A Time for Cautious Optimism

After a year marked by inflationary pressures, geopolitical instability and the world returning to a new normal post-COVID-19 pandemic, our third annual FTI Consulting Survey: U.S. Healthcare & Life Sciences Industry Outlook asked 250 industry leaders for their expectations for the sector in 2023. Emerging trends include adopting a cautiously optimistic outlook for the year ahead due to the expected increase in financial investment in the sector, a need to be better prepared for potential cybersecurity threats and a greater focus on environmental, social and governance (ESG) initiatives.

Healthcare and Life Sciences Quarter in Review Read Now

This year’s survey comes off the back of positive momentum over the past few years for the industry. Driven by life-altering medical innovations, including gene and cell therapy, enhanced public perceptions of the sector due to the COVID-19 pandemic and relentless demand for more scientific and technical talent, the healthcare and life sciences sector has experienced an increased level of attention from a wide variety of stakeholders. Given how much the political and economic landscape has changed over the course of 2022, however, the question is what lies ahead.

FTI Consulting conducted its third annual survey of 250 senior decision makers working in corporate communications, investor relations, public affairs, business development and marketing for healthcare and life sciences companies in the U.S. to understand the key trends and challenges currently facing the industry.

Click here to download the full report